Home  |  Contact

Cellosaurus LIM1215 R3 Cetux (CVCL_A2CC)

Cell line name LIM1215 R3 Cetux
Accession CVCL_A2CC
Resource Identification Initiative To cite this cell line use: LIM1215 R3 Cetux (RRID:CVCL_A2CC)
Comments Population: Caucasian.
Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
Derived from site: Metastatic; Omentum; UBERON=UBERON_0003688.
Sequence variations
  • Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Lynch syndrome (NCIt: C8494)
Lynch syndrome (ORDO: Orphanet_144)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2574 (LIM1215)
Sex of cell Male
Age at sampling 34Y
Category Cancer cell line
Publications

PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821
Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I., Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M., Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J., Dalmases A., Bellmunt J., De Fabritiis G., Rovira A., Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.
Clin. Cancer Res. 21:2157-2166(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_A2CC
Encyclopedic resources Wikidata; Q105509901
Polymorphism and mutation databases Cosmic; 2841369
Entry history
Entry creation12-Jan-2021
Last entry update05-Oct-2023
Version number5